PLX034424

GSE146850: Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance

• Organsim human
• Type RNASEQ
• Target gene
• Project ARCHS4

EGFR tyrosine kinase inhibitors (EGFR TKIs) are the standard of care treatment for patients with EGFR-mutant lung adenocarcinoma (LUAD). Although initially effective, EGFR TKIs are not curative. Disease inevitably relapses due to acquired drug resistance. Here, we tested the ability of 1,25(OH)2D3 to promote epithelial differentiation and restore EGFR TKI sensitivity in models of EGFR TKI resistance that were associated with epithelialmesenchymal transition (EMT). SOURCE: Eduardo Cortes (eduardo.cortesgomez@roswellpark.org) - ROSWELL PARK CANCER INSTITUTE